Purpose of study:
This project is being done so that scientist can study the effects of the drugs serine and fenofibrate on lipids (fats) in the blood of people affected with MacTel Type 2. Patients with MacTel type 2 tend to have increased lipid levels and we want to see if these drugs can help reduce these lipids.
What is Macular Telangiectasia Type 2?
Macular telangiectasia type 2 (MacTel) is an age-related condition of the macula that effects both eyes and may cause progressive loss of vision.
What is involved in this project?
To enroll in this project, you must already be or also enroll into the “MacTel Natural History Observation and Registry for MacTel Type2” project.
The SAFE study will last 11 weeks with 5 visits occurring at the Eye Institute. During these visits we will ask general questions about your medical history, medications you are on, complete blood draws and we may also take a few images of the back of your eye.
If you are enrolled, you will have an equal chance of being assigned either the drug serine or fenofibrate or both. You may also be assigned to receive no drug. You will be told what drug you are receiving.
Research volunteers will be compensated $50 for the completion of each study visit. In specific circumstances, reasonable travel expense reimbursement may be provided with the sponsor’s approval. If you have questions about whether or not you will be reimbursed for travel, please speak with your study doctor.
You may be eligible to participate in the study if you meet these criteria:
- You are 21 years or older.
- You have been told by a doctor that you have Macular Telangiectasia Type 2
- You are enrolled in the MacTel Natural History Observation and Registry for MacTel Type2” project or willing to enroll
- You are not currently taking a serine or glycine supplement or an anticoagulant
- You are not currently taking or have recently taken a fibrate drug
IRB Approval: PRO41070, 1/10/2022